Bone Biologics Corp

We are a medical device company focused on bone regeneration in spinal fusion. Our primary product uses the recombinant human protein NELL-1, which, when combined with demineralized bone matrix (DBM), is an osteopromotive recombinant protein designed to control bone regeneration. We hold an exclusive worldwide license for the NELL-1 technology platform, obtained through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents ("UCLA TDG"). The U.S. Food and Drug Administration ("FDA") has classified NELL-1/DBM as a device/drug combination product, requiring an FDA-approved pre-market approval ("PMA") application for commercialization in the United States. Founded in 2004 by University of California professors, an Osaka University professor, and a University of Southern California surgeon, we began as a privately held company with proprietary, patented platform technology. This technology has been validated in sheep and non-human primate models for facilitating bone growth. We are a clinical-stage entity, with lead product development and clinical studies concentrated on spinal fusion surgery. Our platform technology is believed to have applications in surgical specialties including spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The production and marketing of our products and ongoing research and development activities in the United States are subject to extensive governmental regulation, including rigorous preclinical and clinical testing and an extensive regulatory approval process by the FDA.